Article - 10/01/2014 HybridKnife – an instrument for future endoscopy Endoscopic and minimally invasive keyhole surgery is increasingly replacing open surgery. For many years now, patients have reaped the benefits of such treatment techniques, which are less stressful than open surgery and usually leave no scarring. People can leave hospital just a few days after treatment, which also contributes to cost savings in healthcare. Endoscopic submucosal dissection (ESD) is a new technique that enables the endoscopic…https://www.gesundheitsindustrie-bw.de/en/article/news/hybridknife-an-instrument-for-future-endoscopy
Press release - 12/10/2009 Methadone for treating brain tumours - finally an effective therapy in sight? Every year, around 5,500 people in Germany are diagnosed with malignant brain tumours. The chances of effectively treating patients with such tumours have barely improved over the last decades. A new therapeutic appears to be promising. Scientists at the Institute of Forensic Medicine at the University Hospital of Ulm have been able to show that methadone has the ability to combat brain tumours.https://www.gesundheitsindustrie-bw.de/en/article/press-release/methadone-for-treating-brain-tumours-finally-an-effective-therapy-in-sight
Press release - 21/09/2010 immatics raises 54 million euros to advance its late stage clinical therapeutic cancer vaccine portfolio immatics biotechnologies GmbH a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer announced today that it has raised 53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics existing pipeline of advanced therapeutic cancer vaccine candidates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-raises-54-million-euros-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine-portf
Article - 06/05/2013 HeLa, a human bauplan in the Petri dish Scientists from EMBL have recently sequenced the genome of HeLa cells, which are the world’s most commonly used human cell line. They found that the HeLa genome and that of normal human cells reveal striking differences, caused by chromothripsis and other aberrations. Some evolutionary researchers believe that HeLa cells are developing a new human bauplan as they adapt to cultivation in the Petri dish. https://www.gesundheitsindustrie-bw.de/en/article/news/hela-a-human-bauplan-in-the-petri-dish
Press release - 28/05/2009 CureVac Begins Clinical Study with mRNA Vaccine CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-begins-clinical-study-with-mrna-vaccine
Press release - 20/08/2012 Viruses with integrated gene switch Scientists of the German Cancer Research Center (DKFZ) with colleagues from the University of Konstanz have developed “RNA switches” which allow them to specifically turn on and off genes in viruses. This will help to enhance regulation of gene therapy and viral therapy of cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/viruses-with-integrated-gene-switch
Press release - 26/10/2020 How to prevent the spread of tumor cells via the lymph vessels What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-prevent-spread-tumor-cells-lymph-vessels
Press release - 05/01/2008 Nycomed files marketing authorisation application for fentanyl spray Nycomed filed a marketing authorisation application with the European Medicines Agency for an intranasal fentanyl spray in Europe. If approved the centralised filing could allow Nycomed to be the first to enter the market in 29 European countries with the fentanyl spray.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-files-marketing-authorisation-application-for-fentanyl-spray
Article - 18/08/2014 The use of human genes as medical products In contrast to medications used for treating disease, gene therapy does not use chemical agents to alleviate or cure disease symptoms. Instead, it involves the introduction of a normal copy of a mutated gene to restore the function of a protein. Gene therapy could also be described as a way of restoring the body’s self-healing process. It is an extremely smart idea that enables the sustainable treatment of diseases which cannot usually be…https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-human-genes-as-medical-products
Article - 30/06/2014 Targeting epigenetic DNA modifications for the diagnosis of cancer Epigenetic DNA modifications have been shown to play a role in carcinogenesis and are therefore a promising target for the early detection of cancer. Dr. Daniel Summerer and his research group at the University of Konstanz have developed a method that enables the direct and site-specific identification of epigenetic changes. The method represents a new approach in the field of epigenetic analysis as well as a major step towards simpler cancer…https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-epigenetic-dna-modifications-for-the-diagnosis-of-cancer
Press release - 16/08/2012 Blood cancer cells initiate signalling cascade Researchers of the University of Freiburg have identified a new mechanism that causes immune cells to convert into malignant cancer cells. In Chronic Lymphocytic Leukaemia CLL one of the most common types of blood cancer in the Western world cells themselves carry the key for the pathogenic transformation the scientists report in the journal Nature. Understanding these underlying mechanisms could facilitate new therapies with reduced side…https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-cancer-cells-initiate-signalling-cascade
Article - 11/12/2008 New drug that targets metastasing breast cancer in clinical phase III trial Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-that-targets-metastasing-breast-cancer-in-clinical-phase-iii-trial
Article - 31/05/2017 Peritoneal cancer – long-term survival with good quality of life Thanks to an innovative treatment procedure that has been in use since 2005, surgeons from Tübingen University Hospital have been able to prolong the survival of patients with peritoneal cancer and give them a higher quality of life. This is done using a technique based on complex surgery followed by immediate intraoperative local chemotherapy on the peritoneum.https://www.gesundheitsindustrie-bw.de/en/article/news/peritoneal-cancer-long-term-survival-with-good-quality-of-life
Article - 26/03/2012 Cancer therapy targets secretory pathways Secretion is a fundamental cellular process. Defects in the secretory pathway have been associated with certain genetic diseases in which the maturation of proteins is disturbed. Non-genetic diseases such as metabolic disorders and cancer have also been linked to a defective secretory pathway. Dr. Hesso Farhan from the University of Konstanz and the Biotechnology Institute Thurgau BITg is investigating possible ways to counteract the development…https://www.gesundheitsindustrie-bw.de/en/article/news/cancer-therapy-targets-secretory-pathways
Article - 18/08/2014 VAXIMM: Vaccines that impede cancer growth VAXIMM GmbH, a young biotechnology company from Mannheim, Germany, specialises in the development of vaccines for cancer treatment. The company’s first product candidate, VXM01, is a live oral vaccine that targets the VEGFR-2 receptor and hence the blood supply of tumours. VXM01 is currently undergoing clinical testing in pancreatic cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/news/vaximm-vaccines-that-impede-cancer-growth
Press release - 22/06/2017 MRI without contrast agents? Yes, with sugar! Scientists from the German Cancer Research Center (DKFZ), in collaboration with colleagues from Heidelberg University Hospital, have been able to visualize brain cancer using a novel MRI method. They use a simple sugar solution instead of conventional contrast agents, which can have side effects in the body.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mri-without-contrast-agents-yes-with-sugar
Press release - 04/03/2009 Plant Pathogen Yields Substance to Fight Neuroblastoma Drug treatment of neuroblastoma, a tumor of the nervous system in children, poses major problems. Therefore, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been searching for substances that are suitable as a basis for developing better drugs. Now they have found a candidate: HC-toxin, which is isolated from a fungal plant pathogen. The substance from the maize pathogen reprograms neuroblastoma cells…https://www.gesundheitsindustrie-bw.de/en/article/press-release/plant-pathogen-yields-substance-to-fight-neuroblastoma
Press release - 23/01/2012 Rigged to explode? An inherited mutation in a gene known as the guardian of the genome is likely the link between exploding chromosomes and some particularly aggressive types of cancer, scientists at the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ) and the University Hospital, all in Heidelberg, Germany, have discovered. Their study, published online in Cell, also presents the first whole genome sequence of a paediatric…https://www.gesundheitsindustrie-bw.de/en/article/press-release/rigged-to-explode
Article - 28/04/2014 Sciomics: antibody microarrays and their broad range of applications Sciomics GmbH is a start-up biotech from Heidelberg with a special focus on protein microarrays. Sciomics produces complex, high-density antibody microarrays for cancer-relevant proteins and offers services for medical research, diagnostics and the industry, including biomarker screening, the verification of biomarker candidates, the analysis and localization of drug targets and their signalling pathways as well as the characterization of…https://www.gesundheitsindustrie-bw.de/en/article/news/sciomics-antibody-microarrays-and-their-broad-range-of-applications
Article - 29/11/2010 CYP2D6 and the oestrogen receptor The medicinal adjuvant therapy of breast cancer is a good example of how important it is being aware that different patients metabolise drugs differently. This knowledge plays a key role in the prescription of effective drugs at the correct dose and in preventing adverse reactions and interactions with concomitant drugs.https://www.gesundheitsindustrie-bw.de/en/article/news/cyp2d6-and-the-oestrogen-receptor
Dossier - 15/03/2010 Vaccine development As the recent discussion on the pros and cons of swine flu vaccinations has shown vaccinations are not very popular in Germany. However people tend to forget that no other medical development has helped people to the same extent as immunisation with vaccines has done. Examples include the discovery of the cow pox vaccination by Edward Jenner in 1796 and all the programmes that have been set up by the Global Alliance for Vaccines and Immunisation…https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccine-development
Press release - 02/11/2020 Juvenile myelomonocytic leukemia: International classification model allows for customized treatment Juvenile myelomonocytic leukemia (JMML) is a rare blood cancer of early childhood. Previous research activities have shown that JMML patients can be divided into three groups based on certain genetic markers, DNA methylation. Depending on the subgroup, statements can be made about the course of the disease. https://www.gesundheitsindustrie-bw.de/en/article/press-release/juvenile-myelomonocytic-leukemia-international-classification-model-allows-customized-treatment
Press release - 16/02/2010 He Who Dares Wins – Million Euro Funding for DKFZ Researcher The European Research Council will provide funding of 2.4 million euro over the next four years to support a research project of Christof Niehrs at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). Niehrs investigates the processes of reactivation of silenced genes in cells. Disruption of this mechanism can cause cancer and other diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/he-who-dares-wins-million-euro-funding-for-dkfz-researcher
Article - 05/06/2008 CureVac: partnership with University of Florida, CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-partnership-with-university-of-florida
Press release - 24/07/2012 Tailor-made viruses for enhanced cancer therapy Parvoviruses specifically kill cancer cells and are already in the clinical trial stage for treating malignant brain tumors. However, as they can also infect normal cells - without doing any harm to them - a large portion of viruses is lost during therapy. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now modified parvoviruses in such a way that they initially lose their ability to infect cells. In…https://www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-viruses-for-enhanced-cancer-therapy